drugset / Trial / NCT00002451

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00002451 ↗

Phase 2 Unknown 8 enrolled Merck Sharp & Dohme LLC
Treatment

Summary

The purpose of this study is to see if it is safe to give indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC) to HIV-positive patients who have never received anti-HIV therapy. This study will look at the effectiveness of this drug combination and side effects.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject INDINAVIR ANHYDROUS Other / unclassified 1200 mg —
Subject Lamivudine Other / unclassified — —
Subject Ritonavir Other / unclassified 200 mg —
Subject Stavudine Other / unclassified — —